Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biopharma boycotts White House meeting

Trump had invited the executives to meet to discuss international reference pricing scheme

Biopharmaceutical industry CEOs informed the White House Monday that they would not attend a meeting that had been scheduled for Tuesday with President Donald Trump.

As a result of the CEO boycott, the White House has canceled the meeting.

Trump announced his meeting with drug company CEOs Friday at a signing ceremony for

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE